TD Cowen analyst Tara Bancroft initiated coverage of TG Therapeutics (TGTX) with a Buy rating and $50 price target The company’s Briumvi is a best-in-class anti-CD20 for relapsing for forms of multiple sclerosis that could rival the “class giants” Ocrevus and Kesimpta, which achieved sales of $9B in 2023, the analyst tells investors in a research note. In the near-term, the firm expects continued launch momentum in Q3 with its $85M sales estimate ahead of consensus. Peak Briumvi U.S. sales could reach $3B, but more expansion strategies are ahead, contends TD.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics price target raised to $38 from $34 at B. Riley
- TG Therapeutics call volume above normal and directionally bullish
- TG Therapeutics presents updated data from ENHANCE Phase 3b trial of BRIUMVI
- TG Therapeutics announces updated data on five-year data from ULTIMATE trials
- S&P announces changes to S&P 400, 600 indexes for quarterly rebalance